Emerging research suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may provide a significant advancement for body treatment. Initial human investigations have shown considerable reductions in visceral tissue, possibly surpassing other body composition therapies . Nevertheless , additional